Short answer
ALUMIS INC. (ALMS) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation signals refreshed investor messaging and may highlight changes in pipeline, strategy, or clinical outlook.
ALUMIS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated corporate presentation signals refreshed investor messaging and may highlight changes in pipeline, strategy, or clinical outlook
- Presentation available on Alumis’ website and furnished as Exhibit 99.1 for investor review
- Disclosure furnished under Regulation FD, limiting treatment as formally filed Exchange Act information
Item EX-99.1 · Exhibit EX-99.1
- Envudeucitinib Phase 3 psoriasis data support a potentially differentiated oral TYK2 profile, with Week 24 PASI 100 responses of 41.0% and 39.5%
- ONWARD1 and ONWARD2 met all primary and secondary endpoints, strengthening the basis for a planned psoriasis NDA filing in Q4 2026
- Safety remained generally manageable through Week 24, with 2.0% serious adverse events and 2.7% discontinuations among overall envudeucitinib-treated patients
- SLE Phase 2b topline data expected in Q3 2026, creating a second major value catalyst and testing broader Type I interferon pathway potential
- A-005 Parkinson’s disease Phase 2 biomarker trial targeted for 1H 2027, extending the pipeline beyond immune-mediated disease
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ALUMIS INC. 8-K filings
Get the next ALMS 8-K as it lands
Follow ALMS for push alerts, or ask the research agent what this filing means.